High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF-β1

References

• Tas F, Erturk K. Acral lentiginous melanoma is associated with certain poor prognostic histopathological factors but may not be correlated with nodal involvement, recurrence, and a worse survival. Pathobiology. 2018;85(4):227–231. doi:10.1159/000488457
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Y, Ma S. Racial differences in six major subtypes of melanoma: descriptive epidemiology. BMC Cancer. 2016;16(1):691. doi:10.1186/s12885-016-2747-6
   PubMed Web of Science ®Google Scholar
• Rapisuwon S, Qin Y, Roszik J, Carapeto F, Patel S, Carvajal R. Systemic Therapy for Mucosal, Acral and Uveal Melanoma. In: Balch CM, Atkins MB, Garbe C, editors. In: Cutaneous Melanoma. Springer International Publishing; 2020:1301–1335.
   Google Scholar
• Jafarian A, Roshan N, Gharib M, et al. Evaluation of cyclooxygenase-2 expression in association with clinical-pathological factors in malignant melanoma. Iran J Pathol. 2019;14(2):96. doi:10.30699/ijp.14.2.96
   Google Scholar
• Seip K. Tumor–microenvironment interactions in malignant melanoma. Impact on metastatic phenotype and drug resistance. Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; 2017: 11–22
   Google Scholar
• Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366–1379. doi:10.1080/15384047.2019.1640032
   PubMed Web of Science ®Google Scholar
• Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15(1):106. doi:10.1186/s12935-015-0260-7
   PubMed Web of Science ®Google Scholar
• Usman HA, Hernowo BS, Tobing MDL, Hindritiani R. The major role of NF-κB in the depth of invasion on acral melanoma by decreasing CD8+ T cells. J Pathol Transl Med. 2018;52(3):164. doi:10.4132/jptm.2018.04.04
   Web of Science ®Google Scholar
• Zhang Y, Kirane A, Huang H, et al. Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer. Mol Cancer Res. 2019;17(2):348–355. doi:10.1158/1541-7786
   Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–4506. doi:10.4049/jimmunol.0802740
   PubMed Web of Science ®Google Scholar
• Muthu AKM, Phaik-Leng Cheah M, Man Fong Chew MBBSM, Yen-Fa Toh MDM. Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix. Malays J Pathol. 2017;39(3):251–255. doi:10.1016/j.ijrobp.2004.04.030
   Web of Science ®Google Scholar
• Zhong W-Q, Chen G, Zhang W, et al. Epithelial-mesenchymal transition in keratocystic odontogenic tumor: possible role in locally aggressive behavior. Biomed Res Int. 2015;2015. doi:10.1155/2015/168089
   Web of Science ®Google Scholar
• Lv J, Dai B, Kong Y, Shen X, Kong J. Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases. Sci Rep. 2016;6(1):1–9. doi:10.1038/srep31432
   PubMed Web of Science ®Google Scholar
• Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review Hashemi. J Cell Physiol. 2019;234(5):5683–5699. doi:10.1002/jcp.27411
   PubMed Web of Science ®Google Scholar
• Jana D, Sarkar DK, Ganguly S, et al. Role of cyclooxygenase 2 (COX-2) in prognosis of breast cancer. Indian J Surg Oncol. 2014;5(1):59–65. doi:10.1007/s13193-014-0290-y
   PubMedGoogle Scholar
• Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. doi:10.1016/j.coi.2014.01.004
   PubMed Web of Science ®Google Scholar
• Obermajer N, Kalinski P. Key role of the positive feedback between PGE2 and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology. 2012;1(5):762–764. doi:10.4161/onci.19681
   PubMed Web of Science ®Google Scholar
• Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014;20(15):4096–4106. doi:10.1158/1078-0432.CCR-14-0635
   PubMed Web of Science ®Google Scholar
• Ghasemi M, Afshar P, Sheidaei S, Moeini Y, Larijani LV. The role of immunohistochemistry expression of COX-2 in differentiating pigmented benign and malignant skin neoplasms. Med J Islam Repub Iran. 2019;33:75. doi:10.34171/mjiri.33.75
   Google Scholar
• Tian M, Schiemann WP. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-β signaling during mammary tumorigenesis. FASEB J. 2010;24(4):1105–1116. doi:10.1096/fj.09-141341
   Web of Science ®Google Scholar
• Lv Z-D, Kong B, Li J-G, et al. Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition. Oncol Rep. 2013;29(1):219–225. doi:10.3892/or.2012.2111
   PubMed Web of Science ®Google Scholar
• Yu X, Buttgereit A, Lelios I, et al. The cytokine TGF-β promotes the development and homeostasis of alveolar macrophages. Immunity. 2017;47(5):903–912. doi:10.1016/j.immuni.2017
   PubMed Web of Science ®Google Scholar
• Jayaraman P, Parikh F, Newton JM, et al. TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. Oncoimmunology. 2018;7(10):e1490853. doi:10.1080/2162402X.2018.1490853
   PubMed Web of Science ®Google Scholar
• Goulet AC, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biology and Therapy. 2003;2(6):713–718.
   Web of Science ®Google Scholar